1. Home
  2. Vol 29, No 5s (2025)
  3. Qian

Clinical application of trastuzumab and docetaxel in the chemotherapy of human epidermal growth factor receptor 2 positive breast cancer patients

Jian Qian(1), Yunxia Xu(2), Xiaokai Ling(3), Fenhua Wang(4),


(1) Department of Thyroid and Breast Surgery, Hangzhou Linping District Maternal & Child Health Care Hospital, Hangzhou 311103, Zhejiang, China
(2) Department of Thyroid and Breast Surgery, Hangzhou Linping District Maternal & Child Health Care Hospital, Hangzhou 311103, Zhejiang, China
(3) Department of Thyroid and Breast Surgery, Hangzhou Linping District Maternal & Child Health Care Hospital, Hangzhou 311103, Zhejiang, China
(4) Department of Thyroid and Breast Surgery, Hangzhou Linping District Maternal & Child Health Care Hospital, Hangzhou 311103, Zhejiang, China
Corresponding Author

Abstract


This study was designed to investigate the effects of trastuzumab combined with docetaxel in the treatment of human epidermal growth factor receptor 2-positive breast cancer patients. Fifty-two human epidermal growth factor receptor 2-positive breast cancer patients accepted chemotherapy at the Hangzhou Linping District Maternal & Child Health Care Hospital from January 2018 to January 2023. They were randomly separated into a control group and a research group. The control group was given docetaxel injection, while in addition to docetaxel injection, the research group was given trastuzumab. The results showed that relative to the control group, the research group had higher objective response rate, higher disease control rate, lower levels of tumor makers and inflammatory cytokines, lower occurrence of adverse events, higher quality of life scores, as well as longer survival time. We conclude that docetaxel plus trastuzumab chemotherapy can promote the clinical efficacy, reduce the levels of tumor markers as well as inflammatory cytokines, lessen the adverse reactions, and promote quality of life and survival time in human epidermal growth factor receptor 2-positive breast cancer patients.

References


Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi

MH, Moradi-Kalbolandi S, Safari E, Farahmand L.

Breast cancer: Biology, biomarkers, and treatments.

Int Immunopharmacol. 2020; 84:106535.

Maughan KL, Lutterbie MA, Ham PS. Treatment of breast

cancer. Am Fam Physician. 2010; 81(11):1339-46.

Zhang YN, Xia KR, Li CY, Wei BL, Zhang B. Review of

Breast Cancer Pathologigcal Image Processing.

Biomed Res Int. 2021; 2021:1994764.

Harbeck N, Gnant M. Breast cancer. Lancet. 2017;

(10074):1134-1150.

Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer

Epidemiology, Prevention, and Screening. Prog Mol

Biol Transl Sci. 2017; 151:1-32.

Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F,

Mokhtari M, Nahand JS, Rahmati M, Mirzaei H,

Kianmehr M. Breast cancer diagnosis: Imaging

techniques and biochemical markers. J Cell Physiol.

; 233(7):5200-5213.

Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E,

Sapino A. Evolving concepts in HER2 evaluation in

breast cancer: Heterogeneity, HER2-low carcinomas

and beyond. Semin Cancer Biol. 2021; 72:123-135.

Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2

heterogeneity in breast cancer. Cancer Treat Rev.

; 100:102286.

Schettini F, Prat A. Dissecting the biological heterogeneity of

HER2-positive breast cancer. Breast. 2021; 59:339

Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab

era: current and upcoming targeted HER2+ breast

cancer therapies. Am J Cancer Res. 2020; 10(4):1045

Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C. HER2

positive breast cancer: Current and new therapeutic

strategies. Breast. 2018; 39:80-88.

Keam SJ. Trastuzumab Deruxtecan: First Approval. Drugs.

; 80(5):501-508.

Dan VM, Raveendran RS, Baby S. Resistance to

Intervention: Paclitaxel in Breast Cancer. Mini Rev

Med Chem. 2021; 21(10):1237-1268.

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V,

Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,

Heeson S, Clark E, Ross G, Benyunes MC, Cortés J.

Pertuzumab, trastuzumab, and docetaxel in HER2

positive metastatic breast cancer. N Engl J Med. 2015;

(8):724-34.

Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman

L, Pedrini JL, Pienkowski T, Knott A, Clark E,

Benyunes MC, Ross G, Swain SM. Pertuzumab plus

trastuzumab plus docetaxel for metastatic breast

cancer. N Engl J Med. 2012; 366(2):109-19.

Arian M, Mirmohammadkhani M, Ghorbani R, Soleimani

M. Health-related quality of life (HRQoL) in beta

thalassemia major (β-TM) patients assessed by 36

item short form health survey (SF-36): a meta

analysis. Qual Life Res. 2019; 28(2):321-334.

de la Mare JA, Contu L, Hunter MC, Moyo B, Sterrenberg

JN, Dhanani KC, Mutsvunguma LZ, Edkins AL.

Breast cancer: current developments in molecular

approaches to diagnosis and treatment. Recent Pat

Anticancer Drug Discov. 2014; 9(2):153-75.

Pondé NF, Zardavas D, Piccart M. Progress in adjuvant

systemic therapy for breast cancer. Nat Rev Clin

Oncol. 2019; 16(1):27-44.

Arciero CA, Guo Y, Jiang R, Behera M, O'Regan R, Peng

L, Li X. ER(+)/HER2(+) Breast Cancer Has Different

Metastatic Patterns and Better Survival Than ER(

)/HER2(+) Breast Cancer. Clin Breast Cancer. 2019;

(4):236-245.

Pernas S, Tolaney SM. Clinical trial data and emerging

strategies: HER2-positive breast cancer. Breast

Cancer Res Treat. 2022; 193(2):281-291.

Lopez-Tarruella S, Echavarria I, Jerez Y, Herrero B, Gamez

S, Martin M. How we treat HR-positive, HER2

negative early breast cancer. Future Oncol. 2022;

(8):1003-1022.

Sheng D, Ma W, Zhang R, Zhou L, Deng Q, Tu J, Chen W,

Zhang F, Gao N, Dong M, Wang D, Li F, Liu Y, He

X, Duan S, Zhang L, Liu T, Liu S. Ccl3 enhances docetaxel chemosensitivity in breast cancer by

triggering proinflammatory macrophage polarization.

J Immunother Cancer. 2022; 10(5)

Demeule M, Charfi C, Currie JC, Larocque A, Zgheib A,

Kozelko S, Béliveau R, Marsolais C, Annabi B.

TH1902, a new docetaxel-peptide conjugate for the

treatment of sortilin-positive triple-negative breast

cancer. Cancer Sci. 2021; 112(10):4317-4334.

von Minckwitz G, Huang CS, Mano MS, Loibl S,

Mamounas EP, Untch M, Wolmark N, Rastogi P,

Schneeweiss A, Redondo A, Fischer HH, Jacot W,

Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C,

DiGiovanna MP, Fasching PA, Crown JP, Wülfing P,

Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski

D, Smitt M, Douthwaite H, Singel SM, Geyer CE, Jr.

Trastuzumab Emtansine for Residual Invasive HER2

Positive Breast Cancer. N Engl J Med. 2019;

(7):617-628.

Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao

X, Jing J. The diagnostic value of serum tumor

markers CEA, CA19-9, CA125, CA15-3, and TPS in

metastatic breast cancer. Clin Chim Acta. 2017;

:51-55.

Hao C, Zhang G, Zhang L. Serum CEA levels in 49 different

types of cancer and noncancer diseases. Prog Mol Biol

Transl Sci. 2019; 162:213-227.

Tang S, Zhou F, Sun Y, Wei L, Zhu S, Yang R, Huang Y,

Yang J. CEA in breast ductal secretions as a promising

biomarker for the diagnosis of breast cancer: a

systematic review and meta-analysis. Breast Cancer.

; 23(6):813-819.

Seale KN, Tkaczuk KHR. Circulating Biomarkers in Breast

Cancer. Clin Breast Cancer. 2022; 22(3):e319-e331.

Einama T, Yamagishi Y, Takihata Y, Suzuki T, Yamasaki

T, Hirose Y, Kobayashi K, Yonamine N, Fujinuma I,

Tsunenari T, Koga M, Ishibashi Y, Nagata K,

Shiraishi T, Nakazawa A, Iwasaki T, Shinto E, Kato

K, Sato K, Ueno H, Kishi Y, Tsuda H. Co-expression

of mesothelin and CA125/MUC16 is a prognostic

factor for breast cancer, especially in luminal-type

breast cancer patients. Biomark Res. 2021; 9(1):78.

Feng QZ, Chen XZ, Sun J, Lu MM, Wang Y, Wang Q,

Zhang C. Analysis of the Effect of Trastuzumab

Combined with Docetaxel on Serum Tumor Markers

in the Treatment of HER-2 Positive Breast Cancer and

Factors Influencing Therapeutic Efficacy. Cancer

Manag Res. 2021; 13:8077-8084.

McAndrew NP, Bottalico L, Mesaros C, Blair IA, Tsao PY,

Rosado JM, Ganguly T, Song SJ, Gimotty PA, Mao

JJ, DeMichele A. Effects of systemic inflammation on

relapse in early breast cancer. NPJ Breast Cancer.

; 7(1):7.


Full Text: PDF

Article Metrics

Abstract View : 947 times
PDF Download : 233 times

Refbacks

  • There are currently no refbacks.